Technology Listings


139 Results Sort By:
Targeted Anti-Cancer Nanoparticle Therapy
Application A drug-carrying nanoparticle that selectively targets cancer cells. Key Benefits Incorporates an already proven anti-cancer therapeutic. Increases deliverability. Targets cancer cells. Market Summary Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 9/9/2019       Inventor(s): Jack Arbiser, Lily Yang
DNAzyme Nanoparticles for the Cleavage of RNA
Application Site-selective RNA splicing nanozyme for cleaving and ligating RNA. Key Benefits Can cleave virtually any RNA stem loop. Removes a 19 nucleotide segment from a 67 nucleotide RNA loop with up to 66% efficiency. Technical Summary Modulating RNA can be useful for studying RNA biology, gene knockdown, and regulating RNA splicing. S...
Published: 9/5/2019       Inventor(s): Jessica Petree, Kevin Yehl, Khalid Salaita
Subunit-Selective Modulator for Treatment of Neurological Disorders
Application Subunit-selective GluN2C and GluN2D positive allosteric modulators of N-methyl-D-aspartic acid receptors (NMDAR) for treatment of neurological disorders. Key Benefits Specifically targets GluN2C/D subunits for positive modulation of NMDAR activity. Higher potency compared to non-selective modulators. Improved drug-like properties...
Published: 8/26/2019       Inventor(s): Matthew Epplin, David Menaldino, Stephen Traynelis, Dennis Liotta
Antibody Therapy for Varicella Zoster Virus
Application Human monoclonal antibodies for the treatment of varicella zoster virus (VZV). Key Benefits Human monoclonal antibodies can limit the spread of VZV. gH-specific antibodies are complement-independent. Market Summary Varicella Zoster Virus (VZV) causes varicella, more commonly known as chickenpox. Once the illness resolves, the v...
Published: 8/19/2019       Inventor(s): Rafi Ahmed, Nicole Sullivan
Beta Blocker Isomers as Angiogenesis Inhibitors
Application β-blocker inactive form of propranolol for treatment of angiogenic disease. Key Benefits Reduced side-effects, such as low blood pressure and low blood sugar. Increased anti-angiogenic activity compared to the active isoform. Market Summary Angiogenesis is the growth of blood vessels from the existing vasculature. While it...
Published: 7/29/2019       Inventor(s): Jack Arbiser
Theranostic Biomarker for Aspirin-Exacerbated Respiratory Disease
Application Biomarkers for a clinical diagnostic tool and non-psychogenic therapy to detect and treat aspirin-exacerbated respiratory disease. Key Benefits Does not rely on aspirin challenge, increasing safety and availability for suspected patients. May be used in patients who have respiratory compromise or are not stable. Minimally-invasiv...
Published: 7/2/2019       Inventor(s): Joshua Levy, Samuel Molina
Small Molecule Inhibitors of Mcl-1 as Anti-Cancer Agent
ApplicationMyeloid cell leukemia 1 (Mcl-1) inhibitor to enhance DNA replication stress sensitivity for cancer therapy.Key BenefitsInhibits DNA repair in cancer cells.Used in combination with existing cancer therapy.Market SummaryChemoresistance occurs when cancer cells develop resistance to chemotherapy drugs, and appearance of chemoresistance grea...
Published: 6/24/2019       Inventor(s): Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
Antibody for the Treatment of Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Application Repurposed monoclonal antibody (mAb) that blocks inflammatory CD4 T cell migration for the treatment of NASH and liver fibrosis. Key Benefits Therapy for treating NASH, NAFLD, and liver fibrosis. Potential reduced approval time due to existing clinical safety data for α4β7 mAb. Market Summary Non-alcoholic steatohepa...
Published: 6/24/2019       Inventor(s): Frank Anania, Khalidur Rahman
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making ant...
Published: 6/18/2019       Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
Small Molecule Inhibitors of NADPH Oxidase 4 (NOX4) Signaling
ApplicationSmall molecule inhibitors of NOX4 signaling with a wide array of therapeutic potential.Key BenefitsSmall molecule inhibitors of NOX4 signaling.Low cytotoxicity.Market SummaryThe NADPH oxidase 4 (NOX4) has gained considerable and growing attention during the past years because of its potential key involvement in a variety of diseases, som...
Published: 5/13/2019       Inventor(s): Bernard Lassegue, Kathy Griendling, David Brown, Qian Xu, Osman Guner, J. Phillip Bowen, Amol Kulkarni, E. Blake Watkins
1 2 3 4 5 6 7 8 9 10 ...